Literature DB >> 9116912

Increased circulating leptin concentrations in insulin-resistant first-degree relatives of patients with non-insulin-dependent diabetes mellitus: relationship to body composition and insulin sensitivity but not to family history of non-insulin-dependent diabetes mellitus.

B Nyholm1, S Fisker, S Lund, N Møller, O Schmitz.   

Abstract

OBJECTIVE: To explore a possible association between serum concentration of leptin, insulin sensitivity and non-insulin-dependent diabetes mellitus (NIDDM).
DESIGN: Forty first-degree relatives of NIDDM patients and 35 control subjects matched for age, gender and body mass index underwent a hyperinsulinaemic (insulin infusion rate 0.6 mU/kg per min) euglycaemic clamp combined with indirect calorimetry. Serum leptin was measured in fasting blood samples obtained before the clamp.
RESULTS: All subjects had a normal oral glucose tolerance test. Insulin-stimulated glucose uptake (M) was decreased in the relatives compared with the control subjects (4.58 +/- 0.27 versus 6.06 +/- 0.25 mg/kg per min, P < 0.001). Conversely, serum leptin was increased in the relatives (9.6 x/divided by 1.1 versus 6.1 x/divided by 1.2 ng/ml (geometric mean x/divided by antilog S.E.M.), P < 0.05). A positive correlation was observed between circulating levels of leptin and percentage body fat (P < 0.001) and inverse correlations were found between leptin, M (P < 0.01), maximal aerobic capacity (VO2 max) (P < 0.01), and energy expenditure (P < or = 0.01) in both groups. In multiple linear regression analysis, percentage body fat, gender and M significantly determined the level of leptin (r2 = 0.71, P < 0.001) whereas family history of NIDDM and VO2 max did not.
CONCLUSION: Serum leptin is increased in insulin-resistant offspring of NIDDM patients. The association between leptin, anthropometric measures and insulin sensitivity is, however, comparable with that of a control group. The increased concentrations of serum leptin in the relatives appear to be associated with the insulin resistance, but not with a family history of NIDDM.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9116912     DOI: 10.1530/eje.0.1360173

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  6 in total

1.  Leptin Attenuates the Contractile Function of Adult Rat Cardiomyocytes Involved in Oxidative Stress and Autophagy.

Authors:  Liu-Jin Luo; Ying-Ping Liu; Xun Yuan; Gui-Ping Zhang; Ning Hou; Xiao-Qian Wu; Jian-Dong Luo; Gen-Shui Zhang
Journal:  Acta Cardiol Sin       Date:  2016-11       Impact factor: 2.672

2.  Autonomic dysregulation in ob/ob mice is improved by inhibition of angiotensin-converting enzyme.

Authors:  Aline M Hilzendeger; Andrey C da Costa Goncalves; Ralph Plehm; André Diedrich; Volkmar Gross; Joao B Pesquero; Michael Bader
Journal:  J Mol Med (Berl)       Date:  2009-12-12       Impact factor: 4.599

3.  Role of leptin in atherogenesis.

Authors:  Laxman Dubey; Zeng Hesong
Journal:  Exp Clin Cardiol       Date:  2006

4.  Effects of diabetes family history and exercise training on the expression of adiponectin and leptin and their receptors.

Authors:  Colin N Moran; Nicholas D Barwell; Dalia Malkova; Steve J Cleland; Ian McPhee; Chris J Packard; Victor A Zammit; Jason M R Gill
Journal:  Metabolism       Date:  2010-02-12       Impact factor: 8.694

5.  Impact of physical inactivity on adipose tissue low-grade inflammation in first-degree relatives of type 2 diabetic patients.

Authors:  Lise Højbjerre; Mette Paulli Sonne; Amra Ciric Alibegovic; Ninna Bo Nielsen; Flemming Dela; Allan Vaag; Jens Meldgaard Bruun; Bente Stallknecht
Journal:  Diabetes Care       Date:  2011-08-11       Impact factor: 19.112

6.  Combined association of maternal and paternal family history of diabetes with plasma leptin and adiponectin in overweight Hispanic children.

Authors:  C Koebnick; L A Kelly; C J Lane; C K Roberts; G Q Shaibi; C M Toledo-Corral; J N Davis; M J Weigensberg; M I Goran
Journal:  Diabet Med       Date:  2008-09       Impact factor: 4.359

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.